Fig 2.

Eligible comparisons for efficacy outcomes of first line and second or later line regimens in network meta-analysis. Network plots illustrate direct and indirect comparisons for overall survival, progression-free survival, and objective response rate. Nodes represent each regimen, with size proportional to number of participants. Lines represent direct comparisons between regimens, with thickness indicating number of direct comparisons. Indirect comparisons arose from combining direct comparisons within the network. BRAF=B-Raf proto-oncogene, serine/threonine kinase; Chemo=chemotherapy; DCT=doublet chemotherapy; EGFR=epidermal growth factor receptor; MEK=mitogen-activated protein kinase kinase; PI3K=phosphoinositide 3-kinase; TCT=triplet chemotherapy; VEGF=vascular endothelial growth factor